Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 4
1965 8
1966 27
1967 28
1968 34
1969 21
1970 19
1971 27
1972 32
1973 25
1974 23
1975 20
1976 22
1977 21
1978 25
1979 15
1980 19
1981 14
1982 8
1983 18
1984 13
1985 19
1986 16
1987 17
1988 13
1989 26
1990 13
1991 14
1992 22
1993 19
1994 30
1995 21
1996 43
1997 42
1998 36
1999 53
2000 53
2001 47
2002 47
2003 52
2004 45
2005 73
2006 65
2007 60
2008 87
2009 70
2010 79
2011 88
2012 103
2013 99
2014 79
2015 61
2016 59
2017 62
2018 70
2019 52
2020 47
2021 46
2022 24
Text availability
Article attribute
Article type
Publication date

Search Results

2,041 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Hudson JI, et al. JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889. JAMA Psychiatry. 2017. PMID: 28700805 Free PMC article. Clinical Trial.
Eligible adults met DSM-IV-R binge-eating disorder criteria and had moderate to severe binge eating disorder (3 binge-eating days per week for 14 days before open-label baseline; Clinical Global Impressions-Severity [CGI-S] scores 4 [moderate severity] at screening and ope …
Eligible adults met DSM-IV-R binge-eating disorder criteria and had moderate to severe binge eating disorder (3 binge-eating days per week f …
Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial.
Thompson RG Jr, Oliveto A, Thostenson JD, Wilson MP, McGaugh J, Mancino MJ. Thompson RG Jr, et al. J Psychopharmacol. 2021 Nov;35(11):1420-1430. doi: 10.1177/02698811211050563. Epub 2021 Oct 26. J Psychopharmacol. 2021. PMID: 34697965 Clinical Trial.
AIMS: Given the association between methamphetamine withdrawal and relapse during early treatment, this study tested a controlled d-amphetamine withdrawal paradigm among methamphetamine-using individuals. ...RESULTS/OUTCOMES: Participants were successfully randomized and s …
AIMS: Given the association between methamphetamine withdrawal and relapse during early treatment, this study tested a controlled d-amphe
Effects of d-amphetamine on simulated driving performance before and after sleep deprivation.
Hjälmdahl M, Vadeby A, Forsman A, Fors C, Ceder G, Woxler P, Kronstrand R. Hjälmdahl M, et al. Psychopharmacology (Berl). 2012 Aug;222(3):401-11. doi: 10.1007/s00213-012-2744-7. Epub 2012 May 26. Psychopharmacology (Berl). 2012. PMID: 22638811 Clinical Trial.
OBJECTIVES: The aims were to assess the effects on fundamental driving parameters during simulated driving of two doses of d-amphetamine and further to assess the interaction between d-amphetamine and sleep deprivation. ...CONCLUSIONS: Our results suggest that admin …
OBJECTIVES: The aims were to assess the effects on fundamental driving parameters during simulated driving of two doses of d-amphetamine
Open-label pilot study of lisdexamfetamine for cocaine use disorder.
Mariani JJ, Choi CJ, Pavlicova M, Mahony AL, Brooks DJ, Grabowski J, Levin FR. Mariani JJ, et al. Am J Drug Alcohol Abuse. 2021 May 4;47(3):402-409. doi: 10.1080/00952990.2021.1885677. Epub 2021 Apr 2. Am J Drug Alcohol Abuse. 2021. PMID: 33797985 Free PMC article. Clinical Trial.
Lisdexamfetamine, a novel prodrug psychostimulant, is roughly 40-50% as potent as dextroamphetamine.Objectives: To evaluate the safety, tolerability, and optimal dosing of lisdexamfetamine for treating CUD.Methods: Open-label, 8-week trial of 17 CUD adults. ...
Lisdexamfetamine, a novel prodrug psychostimulant, is roughly 40-50% as potent as dextroamphetamine.Objectives: To evaluate the safet …
Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC, Findling RL, Wu J, Kollins SH, Wang Y, Martin P, Robertson B. Childress AC, et al. J Child Adolesc Psychopharmacol. 2020 Apr;30(3):128-136. doi: 10.1089/cap.2019.0117. Epub 2020 Feb 11. J Child Adolesc Psychopharmacol. 2020. PMID: 32233956 Free PMC article. Clinical Trial.
Methods: This phase 2, multicenter, open-label, dose-optimization study (ClinicalTrials.gov registry: NCT02402166) was conducted at seven U.S. sites between April 15, 2015, and June 30, 2016. Children (4-5 years of age) meeting Diagnostic and Statistical Manual of Mental D …
Methods: This phase 2, multicenter, open-label, dose-optimization study (ClinicalTrials.gov registry: NCT02402166) was conducted at seven U. …
Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects.
Dolder PC, Strajhar P, Vizeli P, Odermatt A, Liechti ME. Dolder PC, et al. Psychopharmacology (Berl). 2018 May;235(5):1389-1402. doi: 10.1007/s00213-018-4849-0. Epub 2018 Feb 9. Psychopharmacology (Berl). 2018. PMID: 29511807 Clinical Trial.
D-Amphetamine and lisdexamfetamine increased cognitive performance (go-accuracy and vigilance on the SST and MCT, respectively). ...Both amphetamines also slightly altered aspects of social cognition. Whether these small effects also influence social interaction beh …
D-Amphetamine and lisdexamfetamine increased cognitive performance (go-accuracy and vigilance on the SST and MCT, respectively). ...B …
Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA, Alperin S, Leon T, Faraone SV. Adler LA, et al. J Child Adolesc Psychopharmacol. 2017 Mar;27(2):196-199. doi: 10.1089/cap.2016.0121. Epub 2016 Dec 9. J Child Adolesc Psychopharmacol. 2017. PMID: 27935735 Clinical Trial.
BACKGROUND: Lisdexamfetamine (LDX) is a prodrug and consists of an active moiety, d-amphetamine, bound to lysine. Clinically, d-amphetamine becomes available postcleavage of the prodrug in the blood stream. Clinical effects of LDX in attention-deficit/hyperactivity …
BACKGROUND: Lisdexamfetamine (LDX) is a prodrug and consists of an active moiety, d-amphetamine, bound to lysine. Clinically, d-am
The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance.
Silber BY, Croft RJ, Papafotiou K, Stough C. Silber BY, et al. Psychopharmacology (Berl). 2006 Aug;187(2):154-69. doi: 10.1007/s00213-006-0410-7. Epub 2006 Jun 8. Psychopharmacology (Berl). 2006. PMID: 16761129 Clinical Trial.
RATIONALE: It is not clear how the deleterious effects of amphetamines on driving performance are mediated in terms of select cognitive processes. ...CONCLUSIONS: The current series of studies primarily provides evidence of low-level amphetamine-related enhancement …
RATIONALE: It is not clear how the deleterious effects of amphetamines on driving performance are mediated in terms of select cogniti …
Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.
Bolin BL, Stoops WW, Sites JP, Rush CR. Bolin BL, et al. J Addict Med. 2016 May-Jun;10(3):156-65. doi: 10.1097/ADM.0000000000000206. J Addict Med. 2016. PMID: 26933876 Free PMC article. Clinical Trial.
Although d-amphetamine and phendimetrazine significantly increased ratings indicative of abuse potential (eg, drug liking) and stimulant-like effects relative to placebo, these increases were generally small in magnitude, with phendimetrazine producing significant effects …
Although d-amphetamine and phendimetrazine significantly increased ratings indicative of abuse potential (eg, drug liking) and stimul …
2,041 results